Drug intelligence / Profile preview

Antipyrine + benzocaine

Development stage
Discontinued
Lead developer
Endo International
Modality
Drug Delivery Systems, Small Molecules
Administration
Otic
01

Overview

Antipyrine + benzocaine is a combination otic (ear) medication used primarily to relieve ear pain and swelling associated with middle ear infections (acute otitis media), as well as to facilitate the removal of excessive or impacted ear wax (cerumen). Antipyrine acts as an analgesic and anti-inflammatory agent by reducing pain and inflammation in the ear. Benzocaine is a local anesthetic that numbs the area to further alleviate discomfort. The combination may be used alongside antibiotics for infection management. This product is typically formulated as an otic solution for administration directly into the external auditory canal[1][2][3][4][5]. The FDA mandated discontinuation of unapproved prescription versions of this drug in 2015 due to regulatory concerns about safety and manufacturing standards; however, it may still be available in some markets or compounded formulations[5]. Some branded products have been reformulated or discontinued.

Brand names
AuralganAurodexAurotoDoloticOtic CareOtiLamAurogard
Other names
A/B otic drops
02

Targets

COXNaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Antipyrine + benzocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antipyrine + benzocaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call